Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine
FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.
You may also be interested in...
From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.
Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.
French pharma reports OTC Xyzal sales up nearly 86% to $14.5m during latest quarter, providing driver for allergy/cough/cold segment of its consumer health business. Total consumer health revenues, including nutritional and personal care products, up 1.1% at a consent exchange rate to $1.3bn during the April-June period.